Friday’s verdict comes at a time when many physicians are rethinking the long-term use of Fosamax and other osteoporosis drugs known as oral bisphosphonates. Last month, the Food and Drug Administration issued a public advisory saying the drugs had been linked with — although not definitively as the cause of — rare thigh fractures. The agency will now require the labels of oral bisphosphonates to state that the optimum duration of taking the drugs is not known
via nytimes.com
1 comment:
This woman had rheumatoid arthritis and was taking long term steroids for it. It was ludicrous for her to blame her jaw bone problem on Fosamax. Any first year nursing student knows the bone demineralization that results from steroids. I'm glad she lost. Merck should countersue her and her ambulance chaser.
Post a Comment